GLP1R and metabolic dysfunction-associated steatotic liver disease: Sodium-glucose transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have recently shown potential efficacy for the treatment of NAFLD/NASH with diabetes [1, 15, 16], but are expected to be more effective for NAFLD/NASH in obese diabetic patients.